Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

The JAK-STAT Signaling Pathway

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Application of Label-Free Detection Using Tapered Optical Fiber System for Head and Neck Cancer and Infectious Biomolecules.

Head & neck·2026

Same author

ETS1 Orchestrates a Hybrid EMT Program Driving Metastasis and Immune Evasion.

Cancer research·2026

Same author

Genome-wide variation in cell-free DNA end-motif entropy predicts immunotherapy response in head and neck cancer.

The Journal of clinical investigation·2026

Same author

Beyond Human Papillomavirus (HPV): Detection of EBV and Polyomaviruses in Cervical and Anal Samples.

Journal of medical virology·2026

Same author

Clinical and translational results from a phase 1 trial of gemcitabine/nab-paclitaxel with nivolumab/ipilimumab or hydroxychloroquine/ipilimumab in untreated metastatic pancreatic adenocarcinoma.

Journal for immunotherapy of cancer·2026

Same author

Precision Epigenetic Reprogramming: CoREST Inhibition Sensitizes STK11-Mutant Tumors to Immune Checkpoint Blockade Therapy.

Cancer research·2025

Search research articles

Related Experiment Video

Updated: Feb 28, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Targeting STAT3 Promotes Tumor Cell Death and Enhances T-Cell Activity in HPV16-Positive Cancer.

Ruben Prins¹, Daniel J Fernandez¹, Diane M Da Silva²

¹Department of Immunology & Immune Therapeutics, USC/Norris Comprehensive Cancer Center, Los Angeles, CA 90033, USA.

|February 27, 2026

Summary

Targeting signal transducer and activator of transcription 3 (STAT3) with CPA-7 inhibits human papillomavirus (HPV) tumor cell growth and enhances anti-tumor immunity. This STAT3 inhibition eradicates early tumors and halts progression in late-stage HPV16+ cancers.

Keywords:

CPA-7 HPV STAT3 T-cell immunity cervical cancer head and neck cancer

More Related Videos

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Describing a Transcription Factor Dependent Regulation of the MicroRNA Transcriptome

Describing a Transcription Factor Dependent Regulation of the MicroRNA Transcriptome

Published on: June 15, 2016

Related Experiment Videos

Last Updated: Feb 28, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Describing a Transcription Factor Dependent Regulation of the MicroRNA Transcriptome

Describing a Transcription Factor Dependent Regulation of the MicroRNA Transcriptome

Published on: June 15, 2016

Area of Science:

Oncology
Immunology
Virology

Background:

Human papillomavirus (HPV) oncoproteins E6 and E7 drive tumor progression in HPV16+ cancers by upregulating IL-6 and IL-23 cytokines.
These cytokines activate signal transducer and activator of transcription 3 (STAT3) signaling in the tumor microenvironment, promoting proliferation and suppressing CD8 T-cell responses.

Purpose of the Study:

To investigate the role of HPV-induced STAT3 signaling in tumor progression.
To evaluate the therapeutic potential of CPA-7, a STAT3 inhibitor, against HPV16+ cancers.

Main Methods:

In vitro studies assessed CPA-7's ability to inhibit STAT3 signaling, reduce proliferation, and induce cell death in HPV16+ C3.43 tumor cells.
In vivo studies in mice bearing C3.43 tumors evaluated CPA-7's effects on HPV-specific T-cell response, tumor growth, and survival.

Main Results:

CPA-7 effectively inhibited STAT3 signaling, reduced proliferation, and caused significant cell death in HPV16+ C3.43 cells in vitro.
In vivo, CPA-7 eradicated early-stage HPV16+ tumors and, in late-stage tumors, increased systemic tumor-specific CD8 T-cells, halting tumor progression.

Conclusions:

Targeting STAT3 signaling effectively reduces tumor cell proliferation and induces cell death in HPV16+ cancers.
STAT3 inhibition enhances the HPV-specific anti-tumor adaptive immune response, leading to reduced progression of late-stage HPV16+ tumors.